WO2020022361A1 - Biomarqueur pour le pronostic du cancer du poumon - Google Patents

Biomarqueur pour le pronostic du cancer du poumon Download PDF

Info

Publication number
WO2020022361A1
WO2020022361A1 PCT/JP2019/028945 JP2019028945W WO2020022361A1 WO 2020022361 A1 WO2020022361 A1 WO 2020022361A1 JP 2019028945 W JP2019028945 W JP 2019028945W WO 2020022361 A1 WO2020022361 A1 WO 2020022361A1
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
kynureninase
survival rate
patients
prognosis
Prior art date
Application number
PCT/JP2019/028945
Other languages
English (en)
Japanese (ja)
Inventor
弘行 鈴木
努 森
哲史 武藤
匠 山浦
Original Assignee
公立大学法人福島県立医科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公立大学法人福島県立医科大学 filed Critical 公立大学法人福島県立医科大学
Priority to JP2020532429A priority Critical patent/JP7114112B2/ja
Publication of WO2020022361A1 publication Critical patent/WO2020022361A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

La présente invention aborde le problème de la prédiction du pronostic d'un patient atteint d'un cancer du poumon avec précision, et de la détermination du plan du traitement du cancer du poumon avec précision. La présente invention concerne un biomarqueur pour prédire le pronostic d'un patient atteint d'un cancer du poumon, qui comprend une protéine kynuréninase ou un fragment peptidique de celle-ci ou un transcrit du gène de la kynurénine ou un fragment d'acide nucléique de celui-ci.
PCT/JP2019/028945 2018-07-24 2019-07-24 Biomarqueur pour le pronostic du cancer du poumon WO2020022361A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020532429A JP7114112B2 (ja) 2018-07-24 2019-07-24 肺癌の予後バイオマーカー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018138907 2018-07-24
JP2018-138907 2018-07-24

Publications (1)

Publication Number Publication Date
WO2020022361A1 true WO2020022361A1 (fr) 2020-01-30

Family

ID=69180458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/028945 WO2020022361A1 (fr) 2018-07-24 2019-07-24 Biomarqueur pour le pronostic du cancer du poumon

Country Status (2)

Country Link
JP (1) JP7114112B2 (fr)
WO (1) WO2020022361A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023074135A1 (fr) * 2021-11-01 2023-05-04 国立研究開発法人国立がん研究センター Procédé et kit de réactifs pour aider à déterminer le pronostic du cancer pulmonaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521412A (ja) * 2004-11-30 2008-06-26 ベリデックス・エルエルシー 肺癌予後判定手段
JP2008237022A (ja) * 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
JP2009502115A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521412A (ja) * 2004-11-30 2008-06-26 ベリデックス・エルエルシー 肺癌予後判定手段
JP2008237022A (ja) * 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
JP2009502115A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 小細胞肺癌の診断方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOTLING, J. ET AL.: "Biomarker Discovery in Non-Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation", CLINICAL CANCER RESEARCH, vol. 19, no. 1, 2 October 2012 (2012-10-02), pages 194 - 204, XP055681088 *
FAHRMANN, J. F. ET AL.: "Elevated kynureninase protein expression is associated with KEAP1 mutant non-small cell lung cancer and is predictive of poor overall survival", CANCER RESEARCH, vol. 76, no. 14, July 2016 (2016-07-01), XP002795014 *
NAMANI, A. ET AL.: "NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer", ONCOTARGET, vol. 8, no. 41, 18 July 2017 (2017-07-18), pages 69847 - 69862, XP055681090 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023074135A1 (fr) * 2021-11-01 2023-05-04 国立研究開発法人国立がん研究センター Procédé et kit de réactifs pour aider à déterminer le pronostic du cancer pulmonaire

Also Published As

Publication number Publication date
JPWO2020022361A1 (ja) 2021-08-05
JP7114112B2 (ja) 2022-08-08

Similar Documents

Publication Publication Date Title
US9182415B2 (en) Use of IMP3 as a prognostic marker for cancer
US20130137584A1 (en) Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
Ahmed Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment
US20190317097A1 (en) Novel Biomarkers for Sub-Typing Pancreatic Ductal Adenocarcinoma
US10538817B2 (en) Method for diagnosing and treating ovarian cancer
Rashed et al. Prognostic significance of the genetic and the immunohistochemical expression of epithelial-mesenchymal-related markers in colon cancer
EP2449383B1 (fr) Procédé de diagnostic pour prédire le risque de récurrence de cancer basé sur des isoformes macroh2a d'histone
WO2019116146A1 (fr) Nouveaux marqueurs pronostiques et théranostiques onco-immunologiques
JP7114112B2 (ja) 肺癌の予後バイオマーカー
US20130149711A1 (en) BARD1 Isoforms in Lung and Colorectal Cancer and Use Thereof
CA3082650A1 (fr) Nouveau variant de cip2a et ses utilisations
WO2008031165A1 (fr) Procédés et compositions pour le diagnostic et le traitement de tumeurs
WO2010123124A1 (fr) Facteur de récurrence et de pronostic pour un cancer solide et son utilisation à des fins cliniques
KR101890392B1 (ko) Ｗｎｔ３ａ를 포함하는 난소암의 진단을 위한 마커 및 조성물
JP7065539B2 (ja) 大腸がんの予後バイオマーカー
WO2014185466A1 (fr) Procédé d'évaluation du pronostic du cancer du pancréas
JP6833226B2 (ja) 大腸がんの予後バイオマーカー
KR101890390B1 (ko) Ｐｙｙ를 포함하는 난소암의 진단을 위한 마커 및 조성물
KR101890389B1 (ko) Ｖａｖ３를 포함하는 난소암의 진단을 위한 마커 및 조성물
KR101890387B1 (ko) Ｆｏｘａ２를 포함하는 난소암의 진단을 위한 마커 및 조성물
KR101890388B1 (ko) Ｌｅｆ１을 포함하는 난소암의 진단을 위한 마커 및 조성물
KR101890391B1 (ko) Ｎｋｘ３―２를 포함하는 난소암의 진단을 위한 마커 및 조성물
KR20210151502A (ko) 방사선 저항성 지표 단백질 및 이의 검출방법
JP2004085305A (ja) 癌の診断方法
BG67180B1 (bg) Метод и кит за откриване на онкофузионен протеин

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19841085

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020532429

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19841085

Country of ref document: EP

Kind code of ref document: A1